The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 14 April 2026•Updated 16 April 2026•

1 min read

hVIVO Secures New Influenza Trial Contract and Launches Unified Branding

Key Facts

1hVIVO signed a contract with Traws Pharma to conduct a human challenge trial for influenza.

about 2 months ago

Version History

Version 2about 2 months ago

What changed: Updated the story to include Cavendish's 'buy' rating, financial forecasts for 2025 and 2026, and the shift in focus toward the company's transitional fiscal outlook.

Version 1about 2 months ago

What changed: The story was updated to include the 11% share price increase, details on the specific drug being tested (tivoxavir marboxil) targeting bird flu, and the trial location at Canary Wharf.

Cavendish has maintained a 'buy' rating and a 16.5p price target for hVIVO, despite forecasting a sharp decline in revenue and profitability for 2025. The firm views 2025 as a transition year as market conditions for Contract Research Organizations (CRO) begin to stabilize. This outlook follows hVIVO's recent contract win with Traws Pharma to conduct human challenge trials for a new influenza antiviral. Financial projections for 2026 anticipate revenues reaching £50.3 million, with high single-digit growth expected to be weighted toward the second half of the year. Additionally, the company has launched a unified brand identity to streamline its service lines and improve operational efficiency. The maintained 'buy' rating underscores analyst confidence in hVIVO's long-term growth trajectory despite near-term fiscal headwinds.